NCT04394975View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

421

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

April 2, 2024

Study Completion Date

January 8, 2025

Conditions

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

Interventions

COMBINATION_PRODUCT

Biological : Toripalimab Drug: Axitinib

Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet

DRUG

sunitinib

Drug: Sunitinib, oral capsule

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04394975 - Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer | Biotech Hunter | Biotech Hunter